| Symbol | AEMD |
|---|---|
| Name | AETHLON MEDICAL INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Surgical & Medical Instruments & Apparatus |
| Address | 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA 92121 |
| Telephone | 619-941-0360 |
| Fax | — |
| — | |
| Website | https://www.aethlonmedical.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000882291 |
| Description | Aethlon Medical Inc is a medical technology company. It is focused on addressing unmet needs in health and biodefense. The company operates through two segments namely Aethlon for therapeutic applications, which represents its therapeutic business activities and ESI for diagnostic applications which signifies diagnostic business activities. It is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and to eliminate life-threatening viruses from the circulatory system. The company generates revenue from Aethlon segment. Additional info from NASDAQ: |
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial EvaluatingHemopurifier®
Read moreNew Form 424B3 - AETHLON MEDICAL INC <b>Filed:</b> 2026-07-07 <b>AccNo:</b> 0001683168-26-005322 <b>Size:</b> 423 KB
Read moreAethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Read moreAethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Read moreNew Form S-1/A - AETHLON MEDICAL INC <b>Filed:</b> 2026-07-01 <b>AccNo:</b> 0001683168-26-005219 <b>Size:</b> 343 KB
Read moreNew Form S-1/A - AETHLON MEDICAL INC <b>Filed:</b> 2026-07-01 <b>AccNo:</b> 0001683168-26-005203 <b>Size:</b> 1 MB
Read moreAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for theHemopurifier®
Read moreNew Form S-1 - AETHLON MEDICAL INC <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001683168-26-005003 <b>Size:</b> 1 MB
Read more(90% Positive) AETHLON MEDICAL INC (AEMD) Announces Enrollment Update for applications Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreAethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04595903 | Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® D… | Na | COVID-19 | Terminated | 2022-06-01 | 2022-11-14 | ClinicalTrials.gov |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Na | Squamous Cell Carcinoma of the Head and Neck | Terminated | 2020-10-22 | 2022-11-14 | ClinicalTrials.gov |
| NCT02215902 | Safety Study of the Aethlon Hemopurifier | Na | End Stage Renal Disease | Terminated | 2014-12-01 | 2017-03-10 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pembrolizumab 200mg IV | Other | Approved | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT04453046 |
| Hemopurifier | Other | Approved | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT04453046 |
| Affinity plasmapheresis | Other | Approved | End Stage Renal Disease | TERMINATED | NCT02215902 |
| Hemopurifier | Other | Approved | COVID-19 | TERMINATED | NCT04595903 |
| Pembrolizumab 200mg IV | DRUG | Approved | Squamous Cell Carcinoma of the Head and Neck | TERMINATED | NCT04453046 |
| Hemopurifier | DEVICE | Approved | COVID-19 | TERMINATED | NCT04595903 |
| Affinity plasmapheresis | DEVICE | Approved | End Stage Renal Disease | TERMINATED | NCT02215902 |